Merck & Co., Inc. (MRK) stock analysis

Merck & Co., Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 7.9/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Merck & Co., Inc. shows trailing revenue of $65.77B, a 76.7% gross margin, net debt of $39.87B, EPS of 4.47, valued at about 4.9x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $130.36
• YTD Return: +22.5%
• Revenue TTM: $65.77B
• Revenue Trend: YoY +4.9%
• Gross Margin: 76.7%
• Net Cash: $-39.87B
• EPS: 4.47
• P/S Ratio: 4.9x

Compare: MRK vs UNH · MRK vs JNJ · MRK vs LLY | Also: UNH, JNJ, LLY, PFE, ABBV, TMO